Healthy Volunteers
Conditions
Brief summary
The primary objective of this study is to evaluate the absolute bioavailability of a single, fixed subcutaneous (SC) dose of aducanumab compared with a single weight-based intravenous (IV) dose of aducanumab in healthy volunteers. The secondary objectives of this study are to assess the safety and tolerability of aducanumab administered SC in healthy volunteers and to characterize additional pharmacokinetic (PK) parameters of a single, fixed SC dose of aducanumab and a weight-based IV dose of aducanumab in healthy volunteers.
Interventions
DRUGAducanumab
Administered as specified in the treatment arm
Sponsors
Eisai Co., Ltd.
Biogen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Have a body mass index (BMI) between 18 and 30 kilograms per meter square (kg/m\^2), inclusive. * Have a negative test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day -1. Key
Exclusion criteria
* History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the investigator. * History of severe allergic, anaphylactic, or systemic hypersensitivity reactions, or of any allergic reactions that in the opinion of the investigator are likely to be exacerbated by aducanumab, the excipients contained in the formulation, and if appropriate, and diagnostic agents to be administered during the study. * Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the investigator, within 90 days prior to screening or between screening and Day -1. * Any immunization or vaccination given within 10 days prior to Day 1 and for 10 days after Day 1. * Current enrollment in any other drug, biological, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days prior to Day -1, or 5 half-lives, whichever is longer. * Prior exposure to the study treatment or previous participation in this study or previous studies with aducanumab. * Mini mental state examination (MMSE) score of \<27 at screening. NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of Aducanumab | Up to Day 85 |
| Maximum Observed Concentration (Cmax) of Aducanumab | Up to Day 85 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECGs) | Up to Day 85 | — |
| Number of Participants with Clinically Significant Abnormalities in Laboratory Assessments | Up to Day 85 | — |
| Area Under the Concentration-Time Curve from Time 0 to Time of the Last Measurable Concentration (AUClast) of Aducanumab | Up to Day 85 | — |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to Day 85 | An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death; in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event. |
| Elimination Half-Life (t½) of Aducanumab | Up to Day 85 | — |
| Volume of Distribution (Vd) or Apparent Volume of Distribution (V/F) of Aducanumab | Up to Day 85 | — |
| Clearance (CL) or Apparent Clearance (CL/F) of Aducanumab | Up to Day 85 | — |
| Time to Reach Maximum Observed Concentration (Tmax) for Aducanumab Administered SC | Up to Day 85 | — |
| Number of Participants with Clinically Significant Abnormalities in Vital Signs | Up to Day 85 | — |
Countries
United States
Outcome results
None listed